ADHD Assessment Pathway

 

The objectives of this assessment pathway are:

  1. To provide a multimodal assessment for ADHD
  2. A complete description of treatment methodologies available for people with ADHD
  3. To answer questions often asked of ADHD and its treatment

Further, the assessment is always based on the most up-to-date research on Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder which is possibly under-recognised in mental health settings and in community both in children (5.29%) and adults (2.5%). ADHD is a highly heritable disorder - 0.76 with a multifactorial pattern of inheritance. Parents and siblings of a child with ADHD are 4 to 5 times more likely to have ADHD.

ADHD is easy to treat with 95% of correctly diagnosed patients (children or adults) responding  to treatment. Methylphenidate is suggested as the first line of pharmacological treatments. For most patients with ADHD symptoms these should be safely managed by the use of a single medication, however there is evidence where methylphenidate immediate release has been added to augment the effect of methylphenidate extended release and also that of Atomoxetine, when the clinical response remains inadequate. There is initial good evidence which suggests that stimulants and alpha-2 agonist combinations may have an additive effect, improving effectively and reducing adverse side effects. The evidence for non-pharmacological treatment of ADHD remains mixed there is some evidence to support the removal of food supplements from the diet of YP with ADHD and combination of psychological treatments and parenting groups with medication could have an added effect. Young people with untreated ADHD are 5 times more likely to develop antisocial behaviour, substance abuse and other co morbid psychiatric disorders.